Tissue Diagnostics Market Analysis

Tissue Diagnostics Market Analysis

Based on product, the market is segmented into consumables and instruments. Consumables are further bifurcated into kits, reagents, antibodies, probes. Instruments are further segmented into scanners, tissue processing systems, slide staining systems. The consumables segment held the largest revenue size over USD 3 billion in 2022 and is estimated to grow USD 7 billion by 2032. The field of tissue diagnostics has witnessed significant technological advancements in recent years. These advancements have led to the development of new and improved consumables that offer higher sensitivity, specificity, and automation capabilities.
 

Based on technology, the tissue diagnostics market is bifurcated into immunohistochemistry (IHC), In-situ hybridization (ISH), digital pathology, special staining, and management. The digital pathology segment is anticipated to witness highest CAGR at 8.6% by 2032. An upsurge in the adoption rate of whole-slide imaging (WSI) among the pathologists, serves as one of the primary factors driving the segment progression. WSI extracts unique tumour traits and measures each component of these characteristics to aid in cancer diagnosis and offer informative clinical measures for tumours.
 

Additionally, this technology streamlines workflow, reduces turnaround times, and enables faster consultation and collaboration among pathologists and other healthcare professionals.
 

Tissue diagnostics market is bifurcated based on the application that includes various fields of oncology such as breast cancer, gastric cancer, prostate cancer, lymphoma, lung cancer, others. The breast cancer segment is anticipated to grow over USD 2 billion by 2032. The is revenue is majorly due to an obesity, tobacco use, postmenopausal hormone therapy, excessive alcohol use, long-term active and passive smoking, and other lifestyle-related habits contribute to the development of breast cancer. Human papillomavirus (HPV) infections, prolonged breastfeeding, fewer pregnancies, radiation exposure in the past, and age-related difficulties are among the primary factors for a surge in the number of cases of breast cancer.
 

The tissue diagnostics market is segmented by end-use into hospitals, research laboratories, and pharmaceutical companies, CROs, and others. Hospitals segment dominated the global market accounting for more than 35% market share in 2022 and is estimated to witness significant revenue by 2032 on account of increased use and efficacy rates of tissue diagnostic treatments by hospitals. Physicians are rapidly shifting from traditional testing processes and to tissue-based diagnostic testing techniques. This is due tissue diagnostic tests shorten turnaround times when compared to traditional approaches.
 

U.S. tissue diagnostics market accounted for more than USD 1 billion in 2022 and will grow momentously more than USD 3 billion by 2032 because of high incidence rate of cancer. Several public programmes are in place to reduce cancer incidence and increase demand for cancer diagnosis supplements in the market for tissue diagnostics. The Cancer Prevention and Control Research Network is a Centres for Disease Control and Prevention flagship programme that focuses on cancer prevention in this region.